Sheldon Spier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sheldon Spier has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Saad Alotaibi
Alberta Children's Hospital, University of Calgary, AB, Canada
2 shared publications - David Wyatt Johnson
Department of Pediatrics, Faculty of Medicine, University of Calgary, Calgary, Canada
1 shared publication - James Harder
Alberta Children's Hospital, University of Calgary, AB, Canada
1 shared publication - Mark Montegomery
Pediatric Pulmonology Consultant, Pediatric Pulmonology Division, Alberta Children Hospital, University of Calgary, Calgary, Canada
1 shared publication Reginald Sauve
Community Health Sciences, Faculty of MEDICINE (Medical School) Graduate Science Education, Paediatrics, University of Calgary, Calgary, Canada
1 shared publication
Latest Publications
- Open Access
- 22 May 2008
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 2 (1) , 171
Bronchial obstruction secondary to idiopathic scoliosis in a child: a case report
Patients with severe idiopathic scoliosis are reported to have significant pulmonary complications, including recurrent chest infections, alveolar hypoventilation and respiratory failure.
- 22 May 2008
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 2 (1) , 171
Open AccessBronchial obstruction secondary to idiopathic scoliosis in a child: a case report
Patients with severe idiopathic scoliosis are reported to have significant pulmonary complications, including recurrent chest infections, alveolar hypoventilation and respiratory failure.
- Open Access
- 12 April 2005
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 5 (1) , 6
Inhaled corticosteroids for abnormal pulmonary function in children with a history of Chronic Lung Disease of Infancy: study protocol [ISRCTN55153521]
Background: There is considerable evidence from the literature that children with chronic lung disease of infancy (CLD) have abnormal pulmonary function in childhood and this could have an impact on their life quality and overall health. There are similarities between CLD and asthma, and corticosteroids are the mainstay treatment for asthma. Many physicians use inhaled corticosteroids in children with CLD with no evidence. Therefore we wish to conduct a randomized double-blinded placebo controlled trial to test for the role of inhaled corticosteroids in children aged from3 to 9 years with a history of CLD. Our primary hypothesis will be that inhaled corticosteroids are beneficial in children with CLD.Methods: Our primary hypothesis is that using inhaled steroids; Beclomethasone Dipropionate (QVAR) 100 mcg 2 puffs 2 times a day for 6 weeks will improve the respiratory system resistance and the quality of life in children with CLD.Discussion: We propose that Beclomethasone Dipropionate (QVAR) will affect the pulmonary function after 6 weeks of treatment. In summary we think that our study will highlight knowledge on whether the use of inhaled steroids is clinically effective for CLD.
- 12 April 2005
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 5 (1) , 6
Open AccessInhaled corticosteroids for abnormal pulmonary function in children with a history of Chronic Lung Disease of Infancy: study protocol [ISRCTN55153521]
Background: There is considerable evidence from the literature that children with chronic lung disease of infancy (CLD) have abnormal pulmonary function in childhood and this could have an impact on their life quality and overall health. There are similarities between CLD and asthma, and corticosteroids are the mainstay treatment for asthma. Many physicians use inhaled corticosteroids in children with CLD with no evidence. Therefore we wish to conduct a randomized double-blinded placebo controlled trial to test for the role of inhaled corticosteroids in children aged from3 to 9 years with a history of CLD. Our primary hypothesis will be that inhaled corticosteroids are beneficial in children with CLD.Methods: Our primary hypothesis is that using inhaled steroids; Beclomethasone Dipropionate (QVAR) 100 mcg 2 puffs 2 times a day for 6 weeks will improve the respiratory system resistance and the quality of life in children with CLD.Discussion: We propose that Beclomethasone Dipropionate (QVAR) will affect the pulmonary function after 6 weeks of treatment. In summary we think that our study will highlight knowledge on whether the use of inhaled steroids is clinically effective for CLD.